Investor Presentation NASDAQ:BLFS

Size: px
Start display at page:

Download "Investor Presentation NASDAQ:BLFS"

Transcription

1 Investor Presentation NASDAQ:BLFS

2 Safe Harbor Statement This presentation contains forward-looking statements, including, but not limited to, statements concerning the company s anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. 2

3 BIOPRESERVATION TOOLS FOR CELLS, TISSUES AND ORGANS

4 Preservation of Biologic Material Drug Discovery Solid Organs Tissue Biopsies Tumor Regenerative Medicine Blood Bone Marrow Allogeneic Transplant Autologous Transplant Biobanking 4

5 Biopreservation Challenges Removed from the body - cells, tissues and organs enter a continuum of degradation a race against time! Survival - Quantity Viability - Quality Function Survival Viability Function Ex Vivo Time Ex Vivo Time Ex Vivo Time Hypothermia (cold chain management) is used to preserve biologic integrity and functional performance. Traditional methods and tools are not optimized and offer limited protection from preservation-induced stress, injury, and death. 5

6 Biopreservation Tools Media and other tools designed to preserve biologics during ex vivo storage Shipping products designed to maintain stability of cells and tissues during transportation from patient to lab and back to patient Goal: maximize effectiveness of biologic based medicine 6

7 BIOPRESERVATION MEDIA

8 Our Biopreservation Media Clinical grade preservation media made per GMP facility and QMS certified to ISO13485 Formulated to mitigate molecular cell stress during refrigeration and freeze/thaw process Serum-free, protein-free, AOF; USP ingredients; US FDA Master Files Patented technology; performance superior to commercial and homemade alternatives; also protected by trade secrets 8

9 Cell Yield Comparison Preserved in traditional home brew Cells are mostly dead Preserved in BioLife HypoThermosol Cells are vital, thriving Human mesenchymal stem cells isolated from bone marrow; condition of cells after 5 days of cold storage, then returned to culture conditions and assayed 24 hours later 9

10 Better Cell Yield = Cost Reductions Source Material Manufactured Cell Products Yield LESS Required = MORE Doses Yield LESS Required to Achieve Desired Therapeutic Effect Cost Cost 10

11 Limited Shelf Life = Cost Adder If distribution range is limited by short shelf-life - multiple production facilities required Increased CAPEX requirements Cell Factory Cell Factory Cell Factory Cell Factory Cell Factory 11

12 Longer Shelf Life = Lower Costs Our products extend shelf life to support worldwide distribution of cellular therapeutics Reduced CAPEX requirements Cell Factory 12

13 biologistex Intelligent, Informed, Precise Biologic Materials Management

14 Cold Chain Biologistics Source Material Preservation Media Temperature Controlled Container Patient Cell Factory Temperature Controlled Container Preservation Media Manufactured Cell Product 14

15 Current Biologistics Reality TIME All vaccines and 70% of biologics are temperature sensitive Regenerative medicine therapies require precise thermal protection during shipment Limited temp stability of traditional shipping containers; cell viability declines; lost and unusable doses Limited use of real-time temperature monitoring and reporting during shipment 15

16 Biologistics Risks Rx Clinical $ Economic Administering a thermally sensitive biologic dose that was exposed to unknown temperature excursions, packout errors or has exceeded it stability period Cost of scrapping biologic source material or manufactured cell products Clinical trial impact from poor biologistics management; lost dose, poor shipping container performance, temperature excursions 16

17 Breakthrough Disruptive Technology Simple, reusable, super insulating shipping container Smart box integrated cellular modem and payload monitoring electronics Cloud-hosted biologistics management app Easy packout process evo Smart Shipper 17

18 Current Solutions Inadequate Foam Coolers Limited performance Technology essentially unchanged for over 25 years Single use Environmental impact Vacuum Panel Shipper Very large footprint; heavy Expensive to ship Complicated assembly Refrigerants must be preconditioned to multiple temperature ranges before use 18

19 Biologistex CCMSM Cloud App Actionable Alerts LIMS/API EVO # Alert: Delivered to St. Luke s Medical Center on 5/5/2015 at 20:08 PST 19

20 Web App SaaS Business Model Real-time Location Biologistex CCM SM EVO # Alert: Package is within 5 miles of destination as of 5/5/2015 at 21:19PST Multiparameter Monitoring Configurable Alerts 20

21 SaaS Business Model Potential to build a base of thousands of shippers deployed throughout the world each generating subscription revenue for rental use and data access 21

22 OTHER SERVICES

23 Contract Manufacturing Services Utilizing excess production capacity Niche provider of aseptic media formulation, fill, and finish services Highly selective opportunities with strong alignment with our capabilities 23

24 OUR MARKETS

25 3 Strategic Markets BIOBANKING DRUG DISCOVERY REGENERATIVE MEDICINE Umbilical cord blood banks Adult stem cell banks Tissue banks Biorepositories Hair transplant physicians Pharmaceutical companies Cell suppliers Toxicity testing labs Commercial cell therapy and tissue engineering companies Hospital-based stem cell transplant centers University-based clinical research labs 25

26 Products Used in 185 Clinical Trials Each successful trial = $0.5-2M/year in revenue Pre-Clinical Phase I Phase II Phase III Solid Tumors Hematologic Malignancies Heart Disease Stroke Joint Disease Vision Loss Immune Disorders All Others

27 Biologistics Addressable Market $500 Million Estimated Addressable Market for Shipping Containers Specialized Packaging $2.6 Billion $4.9 Billion $3.2 Billion $5.1 Billion Transportation Source: IMS Health, Evaluate Pharma Source: imarc Group, December

28 Growing Demand for Biopreservation Media $345 Million $820 Million Major growth expected from Regenerative Medicine segment Source: Biopreservation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, (Transparency Market Research, April, 2014) 28

29 INVESTMENT OPPORTUNITY

30 NASDAQ: BLFS Complementary tools extend shelf life and increase survival of cells and tissues IP embedded in more than 185 clinical trials 25% annual core products revenue growth $8.5M cash and no debt at end of Q1 30

31 Significant Long-Term Growth Drivers $ Biopreservation unmet needs Increased regulatory scrutiny Increased commercial risk; trial failure Smart, high performance containers The Internet of Things; SaaS Model Regen Med Franchise Building the Pipeline Capturing Value Revenue and Profit Growth; Enterprise Value 31

32 500+ existing customers Products used in rapid growth biobanking and drug discovery markets >185 Regenerative medicine clinical projects and trials using BioLife products New SaaS offering will revolutionize biologistics management $100M Current production revenue capacity Significant Growth Potential 32

33 Investment Fundamentals March 31, 2015 Cash and Investments $8.6M Total Debt $0.00 Total Stockholder Equity $12.7M Shares Outstanding 3/25/14 issued 3.6M shares at $4.30 Options most in the money Warrants most at $4.75 debt conversion/equity raise 12M 1.4M 7.4M Average Volume ~100,000 shares Market Cap ~$25M Public Float 52% 33

34 NASDAQ:BLFS BioLife Solu5ons, Inc Monte Villa Parkway, Suite 310 Bothell, WA For addi(onal ques(ons or comments, please contact: Michael Rice President and CEO (425) Daphne Taylor CFO, VP - Finance & AdministraHon (425)

BIOLIFE SOLUTIONS INC

BIOLIFE SOLUTIONS INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING BIOLIFE SOLUTIONS INC Form: 8-K Date Filed: 2016-01-07 Corporate Issuer CIK: 834365 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

OneMedForumSF 2012 Conference. January 10th

OneMedForumSF 2012 Conference. January 10th OneMedForumSF 2012 Conference January 10th Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by

More information

AMAG to Acquire Cord Blood Registry

AMAG to Acquire Cord Blood Registry to Acquire Cord Blood Registry June 29, Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE

More information

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem

More information

FEATURE ARTICLE BIOLIFE PRODUCTS IN REGEN MED CLINICAL TRIALS. Volume 4 - Issue 2 Winter 2013 BIOLIFE SOLUTIONS CONTRACT MEDIA MANUFACTURING

FEATURE ARTICLE BIOLIFE PRODUCTS IN REGEN MED CLINICAL TRIALS. Volume 4 - Issue 2 Winter 2013 BIOLIFE SOLUTIONS CONTRACT MEDIA MANUFACTURING Volume 4 - Issue 2 Winter 2013 PHACILITATE S 9TH ANNUAL CELL & GENE THERAPY FORUM WASHINGTON, DC FEATURE ARTICLE BIOLIFE PRODUCTS IN REGEN MED CLINICAL TRIALS BIOLIFE SOLUTIONS CONTRACT MEDIA MANUFACTURING

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

IWK September 22, 2010. Cord Blood Program

IWK September 22, 2010. Cord Blood Program IWK September 22, 2010 Cord Blood Program Discussion Topics Insception s core values and core purpose Insception s experience Umbilical Cord Blood Stem cell Uses Insception Services in a Hospital Partnership

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020

More information

CORD BLOOD BANKING FAQ

CORD BLOOD BANKING FAQ CORD BLOOD BANKING FAQ Cord Blood & Stem Cells Q: What is umbilical cord blood (UCB)? A: Bone marrow, peripheral blood and UCB constitute the three primary sources of stem cells. Cord blood, which, until

More information

Cord Blood America, Inc.

Cord Blood America, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cord Blood America, Inc. Form: 8-K Date Filed: 2013-05-20 Corporate Issuer CIK: 1289496 Symbol: CBAI SIC Code: 8071 Fiscal Year End: 12/31 Copyright 2014,

More information

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED

Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED Comprehensive Medical Waste and Unused Medication Management Solutions Provider NASDAQ: SMED INVESTOR PRESENTATION NOVEMBER Safe Harbor These slides contain (and the accompanying oral discussion will contain)

More information

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma 1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord

More information

Cellular Therapy and Cord Blood Market Report 2013 Page 1. Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences

Cellular Therapy and Cord Blood Market Report 2013 Page 1. Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences Cellular Therapy and Cord Blood Market Report 2013 Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences k.gray@selectbio.com Select Biosciences Market Reports Website: SelectBiosciences.com/marketreports/

More information

HemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy

HemaCare Corporation Company Overview. Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy HemaCare Corporation Company Overview Comprehensive Product and Service Solutions for BioResearch and Cellular Therapy 2015 HemaCare Corporation Leading provider of apheresis products, human blood cells,

More information

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine Stem Cells and Inner Ear Cell Regeneration Stefan Heller Stanford University School of Medicine Embryonic stem cells Induced pluripotent stem cells Somatic stem cells 50 µm Derived from the inner cell

More information

Customizing the Cold Chain. The growing need for targeted temperature-control solutions.

Customizing the Cold Chain. The growing need for targeted temperature-control solutions. Customizing the Cold Chain The growing need for targeted temperature-control solutions. Nils Markmann, Director, Global Operations Andreas Kjällander, Head of Temperature-Control Management Market summary

More information

ThermoGenesis Corp. May 2012

ThermoGenesis Corp. May 2012 ThermoGenesis Corp. May 2012 Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM APPENDIX A SAMPLE CONSENT FORM CORD BLOOD TRANSPLANTATION (COBLT) STUDY SAMPLE CONSENT FORM FOR THE EXPANDED ACCESS PROTOCOL You (your child) are being asked to take part in a clinical research study.

More information

TERUMO Corporation Business Strategy Conference

TERUMO Corporation Business Strategy Conference TERUMO Corporation Business Strategy Conference THERAPEUTIC SYSTEMS & CELL PROCESSING MARK FLOWER GLOBAL MARKETING December 5, 2011 Regenerative Medicine, Cell Therapy, & Cell Processing Regenerative Medicine

More information

Hippocrates, Cords and Quality

Hippocrates, Cords and Quality Hippocrates, Cords and Quality Transfusion Medicine Resident Education Seminar April 3,2012 Renee Naiman, Director, Quality and Regulatory Affairs Overview -Brief update of cord blood history and usage.

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

AssureImmune. Cord Blood: For Something That Precious, Bank with the Best. Important Facts for When You re Expecting. AssureImmune.

AssureImmune. Cord Blood: For Something That Precious, Bank with the Best. Important Facts for When You re Expecting. AssureImmune. AssureImmune AssureImmune Cord Blood: For Something That Precious, Bank with the Best Important Facts for When You re Expecting Banking your baby s umbilical cord blood could be a potentially lifesaving

More information

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries Tokyo, February 10, 2016 - Astellas Pharma Inc. (TSE: 4503, President and

More information

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter)

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions. Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.com Biopreservation What s the issue? Biopreservation considerations

More information

House Resolution No. 37

House Resolution No. 37 california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical

More information

IMS Health to Acquire Cegedim s Information Solutions And CRM Businesses

IMS Health to Acquire Cegedim s Information Solutions And CRM Businesses News For Immediate Release Contacts: Tor Constantino Tom Kinsley Media Relations Investor Relations +1.484.567.6732 +1.203.448.4691 tconstantino@us.imshealth.com tkinsley@imshealth.com IMS Health to Acquire

More information

Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc.

Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc. Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc. to serve patients Enbrel (etanercept) EPOGEN (Epoetin alfa) Aranesp (Darbepoetin alfa) Sensipar (cinacalcet HCl) Vectibix (panitumumab) We aspire

More information

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field

A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare

More information

Cellular Therapy and Cord Blood 2013 Market Report

Cellular Therapy and Cord Blood 2013 Market Report Brochure More information from http://www.researchandmarkets.com/reports/2393891/ Cellular Therapy and Cord Blood 2013 Market Report Description: This is the most up-to-date market report focusing on Cellular

More information

Great Basin Reports 2015 Second Quarter Results and Business Update

Great Basin Reports 2015 Second Quarter Results and Business Update Great Basin Reports 2015 Second Quarter Results and Business Update Company Reports 122 Revenue-Generating Customers, Reaffirms Guidance of 170-180 Customers by Year End SALT LAKE CITY, August 12, 2015

More information

Craig Hallum Conference Investor Presentation

Craig Hallum Conference Investor Presentation Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS 1 DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements as defined within applicable securities laws and regulations. All statements in this presentation,

More information

It s not something you want to think about, but it s something you want to prepare for.

It s not something you want to think about, but it s something you want to prepare for. It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime

More information

Corporate Overview. April 2014 OTCQB: LCDX

Corporate Overview. April 2014 OTCQB: LCDX Corporate Overview April 2014 OTCQB: LCDX Company Snapshot biopsy Provides non-invasive, point-of-care cellular imaging technologies VivaScope systems can improve patient outcomes while reducing costs

More information

Cord Blood America, Inc.

Cord Blood America, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cord Blood America, Inc. Form: 8-K Date Filed: 2007-04-03 Corporate Issuer CIK: 1289496 Symbol: CBAI SIC Code: 8071 Fiscal Year End: 12/31 Copyright 2014,

More information

US Regulations for Import and Export of Cell Therapy Products

US Regulations for Import and Export of Cell Therapy Products US Regulations for Import and Export of Cell Therapy Products Kurt Gunter, MD U Minnesota UCB Transplants (2001-2007)* Total units: 790 Number US banks: 19 Number non-us banks: 12 % units from non-us banks:

More information

15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015.

15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com. April 17, 2015. 15350 Sherman Way, Suite 350 Van Nuys, CA 91406 Phone 877-310-0717 Fax 818-251-5300 www.hemacare.com April 17, 2015 Dear Shareholder, We are experiencing exciting times at HemaCare. Over the course of

More information

5 Frequently Asked Questions About Adult Stem Cell Research

5 Frequently Asked Questions About Adult Stem Cell Research 5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers

More information

THERMOGENESIS REPORTS THIRD QUARTER RESULTS; REDUCES NET LOSS BY 60 PERCENT

THERMOGENESIS REPORTS THIRD QUARTER RESULTS; REDUCES NET LOSS BY 60 PERCENT THERMOGENESIS REPORTS THIRD QUARTER RESULTS; REDUCES NET LOSS BY 60 PERCENT RANCHO CORDOVA, CA, (May 6, 2009) ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,

More information

SAP The World s Leading Business Software Company. Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014

SAP The World s Leading Business Software Company. Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014 SAP The World s Leading Business Software Company Rainer Zinow, Senior Vice President SAP Cloud, SAP SE Frankfurt am Main, September 9, 2014 Safe Harbor Statement Any statements contained in this document

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

Watson to Gain Ability to See with Planned $1B Acquisition of Merge Healthcare Deal Brings Watson Technology Together with Leader in Medical Images

Watson to Gain Ability to See with Planned $1B Acquisition of Merge Healthcare Deal Brings Watson Technology Together with Leader in Medical Images Watson to Gain Ability to See with Planned $1B Acquisition of Merge Healthcare Deal Brings Watson Technology Together with Leader in Medical Images Armonk, NY and CHICAGO -- [August 6, 2015]: IBM (NYSE:

More information

What we will discuss today

What we will discuss today Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources

More information

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully

More information

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

SAP The World s Leading Business Software Company

SAP The World s Leading Business Software Company SAP The World s Leading Business Software Company Luka Mucic, Member of the Executive Board of SAP SE, CFO and COO, SAP SE Munich, September 24, 2014 Safe Harbor Statement Any statements contained in this

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS

CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL FISCAL 2014 RESULTS Company Completes Year of Transformation, Makes Regulatory Advances in Clinical Programs RANCHO CORDOVA September 29, 2014 Cesca Therapeutics

More information

[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)]

[Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)] [Indian Stem Cell Banking Market: Trends & Opportunities (2012-2017)] Executive Summary Stem Cells have a remarkable ability to develop in various body cells of a human. These occur in the earliest stages

More information

Minimize overspend by gaining visibility of total demand

Minimize overspend by gaining visibility of total demand Minimize overspend by gaining visibility of total demand Patti Seymour 9th Annual Clinical Trials Supplies and Packaging October 10-12, 2011 BioProcess Technology Consultants www.bptc.com Supply and Demand

More information

Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014

Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00

More information

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping Equine Stem Cells Sources, Processing, Expansion, Storage and Shipping Sean Owens, DVM, Diplomate ACVP Medical Director, UC Davis Veterinary Regenerative Medicine Laboratory What is a Stem Cell and What

More information

Mark Rohlfing. Vice President of Operations Almac Clinical Services Souderton, Pennsylvania

Mark Rohlfing. Vice President of Operations Almac Clinical Services Souderton, Pennsylvania Mark Rohlfing Vice President of Operations Almac Clinical Services Souderton, Pennsylvania Confidential Almac Group 2014 Who We Are Almac is a global drug development services provider. Our mission is

More information

Sepax. your child s cord blood is in safe hands. World leader in adult stem cell processing

Sepax. your child s cord blood is in safe hands. World leader in adult stem cell processing Sepax your child s cord blood is in safe hands World leader in adult stem cell processing Biosafe Experience Credibility Innovation Dear Customer, Innovation in cell processing is our credo and this is

More information

UMBILICAL CORD BLOOD COLLECTION

UMBILICAL CORD BLOOD COLLECTION UMBILICAL CORD BLOOD COLLECTION by Frances Verter, PhD Founder & Director, Parent's Guide to Cord Blood Foundation info@parentsguidecordblood.org and Kim Petrella, RN Department of Obstetrics and Gynecology

More information

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced

More information

Nokia Conference Call 2Q 2012 Financial Results

Nokia Conference Call 2Q 2012 Financial Results Nokia Conference Call 2Q 2012 Financial Results July 19, 2012 15.00 Helsinki time 8.00 New York time Stephen Elop President & CEO Timo Ihamuotila CFO Matt Shimao Head of Investor Relations 1 Disclaimer

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today. 1 Who is the most influential figure in cord blood around the world? What do you think has been the biggest achievement within the cord blood sector? Which is the most important development in cord blood

More information

Discover the Possibilities Born With Your Baby

Discover the Possibilities Born With Your Baby Discover the Possibilities Born With Your Baby Your Simple Guide to Saving Cord Blood The Power and Promise The lifesaving power of cord blood and regenerative healing potential of cord blood and cord

More information

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults

More information

C O R P O R AT E P R E S E N TAT I O N. NASDAQ: BBSI September 2015

C O R P O R AT E P R E S E N TAT I O N. NASDAQ: BBSI September 2015 C O R P O R AT E P R E S E N TAT I O N NASDAQ: BBSI September 2015 FORWARD-LOOKING STATEMENTS Statements in this presentation about future events or performance, including expectations for gross revenues

More information

Cord Blood Bank Business Plan

Cord Blood Bank Business Plan Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page

More information

Jefferies Healthcare Conference

Jefferies Healthcare Conference Jefferies Healthcare Conference Marc Naughton Executive Vice President and Chief Financial Officer June 2, 2015 Safe Harbor Statement This presentation may contain forward-looking statements, including

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG

Biotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its

More information

Stem Cell Collection Preservation Research Processing. 8651 East Seven Mile Detroit, MI 48234 313-269-7606 313-366-0317 fax WWW.EQUI-STEM.

Stem Cell Collection Preservation Research Processing. 8651 East Seven Mile Detroit, MI 48234 313-269-7606 313-366-0317 fax WWW.EQUI-STEM. Staples Print Solutions BROCHURE QL1 1234 CYANMAGENTAYELLOWBLACK 08/24/2015 MISSION STATEMENT Equi-Stem LLC dedicates itself to being the leading equine stem cell preservation company in the world, offering

More information

Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update

Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

Safe Harbor Provision

Safe Harbor Provision Q2 2015 Safe Harbor Provision In accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors

More information

STEMMED IMPLANT TECHNOLOGY INC. EXECUTIVE SUMMARY

STEMMED IMPLANT TECHNOLOGY INC. EXECUTIVE SUMMARY STEMMED IMPLANT TECHNOLOGY INC. EXECUTIVE SUMMARY 1 INVESTOR BROCHURE Safe Harbour / Disclaimer This presentation may contain forward-looking statements, which reflect the Company's current expectation

More information

The Future of Consumer Health Care

The Future of Consumer Health Care The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More

More information

International NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007

International NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007 International NetCord Foundation Executive Committee Conference Call Minutes Committee Members: Board Members: Staff: President Joan Garcia and Drs. Yves Beguin and Elizabeth Shpall Drs. Cristina Navarrete

More information

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began

More information

Top Ten Things to Know About Stem Cell Treatments

Top Ten Things to Know About Stem Cell Treatments Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of

More information

Immunovaccine Inc. (TSX-V: IMV) July 2011

Immunovaccine Inc. (TSX-V: IMV) July 2011 Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities

More information

Cold Chain Shipping: Protecting Temperature Sensitive Products. Diane McLean Pfizer Global Manufacturing

Cold Chain Shipping: Protecting Temperature Sensitive Products. Diane McLean Pfizer Global Manufacturing Cold Chain Shipping: Protecting Temperature Sensitive Products Diane McLean Pfizer Global Manufacturing January 8, 2009 1 What is Cold Chain? The term cold chain or cold chain management refers to controlled

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Detecting Cancer in Blood. Company presentation

Detecting Cancer in Blood. Company presentation Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements

More information

The therapies are focused in cardiovascular, orthopedics and neurological indications.

The therapies are focused in cardiovascular, orthopedics and neurological indications. 1 2 CescaTherapeutics is (to our knowledge) the first company to integrate all of the essential: 1. Cell friendly devices, 2. Proprietary cell formulations, and Strict clinical steps to ensure the autologous

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015

Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015 Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,

More information

Annual General Meeting Business Update. William M. Tatham, CEO

Annual General Meeting Business Update. William M. Tatham, CEO Annual General Meeting Business Update William M. Tatham, CEO May 22, 2013 1 Disclaimer Certain statements in this presentation, including statements about the financial conditions, and results of operations

More information

We do what we say we will do.

We do what we say we will do. We do what we say we will do. Investor Presentation 1 November 2013 Forward-Looking Statements Certain statements in this document are forward-looking statements, which reflect management s current beliefs

More information

Heat Biologics, Inc. (Exact name of registrant as specified in charter)

Heat Biologics, Inc. (Exact name of registrant as specified in charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event

More information

THE EXPLORATION EQUIPMENT SUPPLIER. GHS 100 Energy Conference June 23, 2015

THE EXPLORATION EQUIPMENT SUPPLIER. GHS 100 Energy Conference June 23, 2015 THE EXPLORATION EQUIPMENT SUPPLIER GHS 100 Energy Conference June 23, 2015 1 Forward-Looking Statement Certain statement and information in this presentation may constitute forward-looking statements within

More information

We do what we say we will do.

We do what we say we will do. We do what we say we will do. Investor Presentation March 2013 1 Forward-Looking Statements Certain statements in this document are forward-looking statements, which reflect management s current beliefs

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine Presented by James Clagett, PhD., Chief Science Officer - The Best Keep Secret in Regenerative Medicine Corporate Headquarters Virginia Beach, VA Who is? helps save lives and restore health for thousands

More information

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT

EDWARDS LIFESCIENCES REPORTS STRONG FIRST QUARTER RESULTS DRIVEN BY SALES GROWTH OF 18.8 PERCENT Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor

More information